A Review of Remdesivir for COVID-19 : Data to Date

Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues regarding accessibility.

Errataetall:

CommentIn: Cardiol Rev. 2020 Nov/Dec;28(6):273-274. - PMID 33017362

Media Type:

Electronic Article

Year of Publication:

2020

Contained In:

Cardiology in review - Vol. 28, No. 6 (2020), p. 332-334

Language:

English

Contributors:

Mehta, Monica
Shyh, Grace I

Links:

Volltext

Keywords:

3QKI37EEHE
415SHH325A
Adenosine Monophosphate
Alanine
Antiviral Agents
Betacoronavirus
Coronavirus Infections
Humans
Journal Article
OF5P57N2ZX
Pandemics
Pneumonia, Viral
Remdesivir
Review
Treatment Outcome

Notes:

Date Completed 14.10.2020

Date Revised 14.10.2020

published: Print

CommentIn: Cardiol Rev. 2020 Nov/Dec;28(6):273-274. - PMID 33017362

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1097/CRD.0000000000000337

PMID:

32773440

PPN (Catalogue-ID):

NLM31441553X